Wave Life Sciences Shares Plunge 55% as Higher Dose of Obesity Drug Fails

Wave Life Sciences (WVE) shares plummeted by more than 55% following disappointing clinical updates regarding its obesity candidate, WVE-007. While higher doses failed to show incremental improvement, new six-month follow-up data for the 240 mg dose revealed a 5% reduction in total fat and a 3% reduction in waist circumference compared to placebo. The updated results also highlighted that the drug stabilized lean mass, recording a slight increase of 2%, which is a critical factor in high-quality weight loss. Despite these specific gains at the lower dose, the lack of efficacy at higher concentrations raised significant concerns about the drug's overall therapeutic profile. This development erased previous market optimism surrounding the company’s GalNAc-siRNA technology targeting the INHBE protein. Investors are now reassessing the firm's competitive standing in the crowded obesity market, marking a major clinical setback for its metabolic pipeline.

Sources:globenewswire.cominvesting.comtipranks.comlifescivoice.comstocktitan.netreuters.combenzinga.comproactiveinvestors.com